Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 309 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients... January 15, 2021 ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... July 21, 2020 2023 ASCO Annual Meeting Research Round Up: Advances in Treating Gynecologic... August 17, 2023 EMA Recommends Extension of Therapeutic Indications for Teclistamab September 11, 2026 Load more HOT NEWS Blind Man Overcomes Life Of Struggles & Becomes An Incredible Woodworker Engaging People with Low-Grade Glioma in Cancer Research ESMO Launches First Congress on Artificial Intelligence and Digital Oncology: A... Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug...
